PDF(Pubmed)
Abstract：
UNASSIGNED: The success of fixation training using microperimetric biofeedback (MP-3 MBFT) in the realm of visual rehabilitation for patients with central vision loss caused by macular pathologies is well established. This study aimed to assess the effectiveness and safety of visual rehabilitation with microperimetric biofeedback in consolidating the benefits obtained, with the goal of reducing the need for repeated intravitreal injections (IVT). Specifically, the focus is on the eyes of patients with central vision loss treated with slow-release corticosteroid IVT following retinal venous thrombosis (RVO), aiming to enhance and maintain postoperative efficacy.
UNASSIGNED: This retrospective review involved the examination of 44 eyes affected by macular edema due to RVO associated with central vision loss. Patients were divided into two groups, with only one undergoing ten sessions of 10-minute visual rehabilitation with a microperimeter (MP-3 MBFT) after IVT over a period of 20 weeks.
UNASSIGNED: All the treated patients demonstrated good tolerance to the procedure, with no reported complications. A comparison of best-corrected visual acuity (BCVA), retinal sensitivity recorded with a microperimeter, and pre-IVT fixation stability revealed statistically significant improvements at the end of the first month after IVT. However, the treatment group continued to exhibit superior and more enduring results at four months post-IV.
UNASSIGNED: The synergistic use of MP-3 MBFT rehabilitation after IVT with slow-release corticosteroids has proven particularly effective in improving BCVA and long-term fixation stability. This led to a significant reduction in the number of required IVTs, with no related adverse events. The authors argue that biofeedback utilization represents a noninvasive therapeutic option devoid of contraindications and easy to implement and that it positively contributes to the overall patient experience regarding quality of life in advanced stages of macular diseases.
UNASSIGNED: This retrospective review involved the examination of 44 eyes affected by macular edema due to RVO associated with central vision loss. Patients were divided into two groups, with only one undergoing ten sessions of 10-minute visual rehabilitation with a microperimeter (MP-3 MBFT) after IVT over a period of 20 weeks.
UNASSIGNED: All the treated patients demonstrated good tolerance to the procedure, with no reported complications. A comparison of best-corrected visual acuity (BCVA), retinal sensitivity recorded with a microperimeter, and pre-IVT fixation stability revealed statistically significant improvements at the end of the first month after IVT. However, the treatment group continued to exhibit superior and more enduring results at four months post-IV.
UNASSIGNED: The synergistic use of MP-3 MBFT rehabilitation after IVT with slow-release corticosteroids has proven particularly effective in improving BCVA and long-term fixation stability. This led to a significant reduction in the number of required IVTs, with no related adverse events. The authors argue that biofeedback utilization represents a noninvasive therapeutic option devoid of contraindications and easy to implement and that it positively contributes to the overall patient experience regarding quality of life in advanced stages of macular diseases.
摘要：
■在由黄斑病变引起的中心视力丧失的患者的视觉康复领域中，使用显微眼周生物反馈（MP-3MBFT）进行固定训练的成功已得到证实。本研究旨在评估微范围生物反馈视觉康复的有效性和安全性，以巩固所获得的益处，目的是减少重复玻璃体内注射（IVT）的需要。具体来说,重点是视网膜静脉血栓形成（RVO）后接受缓慢释放皮质类固醇IVT治疗的中央视力丧失患者的眼睛，旨在提高和维持术后疗效。
■这项回顾性审查涉及对44只眼的检查，这些眼由于与中心性视力丧失相关的RVO而受到黄斑水肿的影响。患者分为两组，在20周的时间内，只有1人在IVT后接受了10次10分钟的微周边视觉康复（MP-3MBFT）。
■所有接受治疗的患者都表现出对手术的良好耐受性，没有报告的并发症。最佳矫正视力（BCVA）的比较，用微周长记录的视网膜敏感度，和IVT前固定稳定性显示，在IVT后的第一个月末，有统计学意义的改善。然而,治疗组在IV后4个月继续表现出优异和更持久的结果.
■IVT后MP-3MBFT康复与缓释皮质类固醇的协同使用已被证明在改善BCVA和长期固定稳定性方面特别有效。这导致所需的IVT数量大幅减少，无相关不良事件。作者认为，生物反馈利用代表了一种无禁忌症且易于实施的非侵入性治疗选择，并且对黄斑疾病晚期患者的生活质量有积极的贡献。
■这项回顾性审查涉及对44只眼的检查，这些眼由于与中心性视力丧失相关的RVO而受到黄斑水肿的影响。患者分为两组，在20周的时间内，只有1人在IVT后接受了10次10分钟的微周边视觉康复（MP-3MBFT）。
■所有接受治疗的患者都表现出对手术的良好耐受性，没有报告的并发症。最佳矫正视力（BCVA）的比较，用微周长记录的视网膜敏感度，和IVT前固定稳定性显示，在IVT后的第一个月末，有统计学意义的改善。然而,治疗组在IV后4个月继续表现出优异和更持久的结果.
■IVT后MP-3MBFT康复与缓释皮质类固醇的协同使用已被证明在改善BCVA和长期固定稳定性方面特别有效。这导致所需的IVT数量大幅减少，无相关不良事件。作者认为，生物反馈利用代表了一种无禁忌症且易于实施的非侵入性治疗选择，并且对黄斑疾病晚期患者的生活质量有积极的贡献。
